Sarepta already have US$1.6bn in the bank so the closing date of the raising is irrelevant.
Sarepta also have a potential US$1.7bn in milestone payments from Roche if they get the gene therapy approved.. paying ANP a sizeable license fee to help increase the chances of those funds being received seems like good business sense don’t you!!
Also, @waynesworld, delving further into Thrombospodin 1 has got me thinking alot longer term about my investment in ANP. No wonder Graham Mitchell mentioned “assured success”.
Where others have failed will Atl1102 succeed ?, page-795
-
- There are more pages in this discussion • 302 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.015(13.0%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $612.7K | 4.843M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56662 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 600000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |